Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of New vs Current Oral Semaglutide in Healthy Subjects
NCT04097600Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2019
- Primary completion
- Dec 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the semaglutide plasma concentration-time curve during a dosing interval at steady state at Day 84. Started Sep 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04097600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04097600.